HOUSE FDA REFORM PROPOSAL BROADENS AGENCY AUTHORITY OVER THIRD-PARTY REVIEWS; DEVICE, FOOD BILLS REMAIN MORE CONTENTIOUS THAN DRUGS/BIOLOGICS REFORMS
Executive Summary
The latest version of the House FDA reform bill for drugs and biologics (HR 3199) would grant the agency the authority to request outside review of all or part of an NDA.